Morgan Stanley Maintains Overweight on Akero Therapeutics, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz maintains an Overweight rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $65 to $70.
June 12, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Akero Therapeutics and raises the price target from $65 to $70.
Morgan Stanley's decision to maintain an Overweight rating and raise the price target for Akero Therapeutics indicates a positive outlook for the company's stock. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100